Kaynak: MarketBeat
Haber Ajansı
Hisse Senedi
Orta Önem
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals NASDAQ: RYTM reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO.
İlgili Semboller
1
R
RYTM
RYTM
Kaynak: MarketBeat
Kaynağı Ziyaret Et